Circulating tumor cells and DNA as liquid biopsies.

PubWeight™: 1.06‹?› | Rank: Top 15%

🔗 View Article (PMC 3979149)

Published in Genome Med on August 23, 2013

Authors

Ellen Heitzer1, Martina Auer1, Peter Ulz1, Jochen B Geigl1, Michael R Speicher1

Author Affiliations

1: Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/8, A-8010 Graz, Austria.

Articles citing this

Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet (2016) 1.50

Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nat Commun (2016) 1.44

Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet (2014) 1.09

Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn (2015) 1.04

The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res (2014) 0.97

Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med (2015) 0.93

The biology of circulating tumor cells. Oncogene (2015) 0.90

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg (2016) 0.87

New blood markers detection technology: A leap in the diagnosis of gastric cancer. World J Gastroenterol (2016) 0.82

High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood. PLoS One (2015) 0.81

The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study. PLoS One (2016) 0.79

Liquid Biopsies for Cancer: Coming to a Patient near You. J Clin Med (2017) 0.78

A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood. J Transl Med (2014) 0.78

Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. Oncotarget (2016) 0.77

Diagnostic and Prognostic Value of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: a systematic review and meta-analysis. Sci Rep (2016) 0.77

The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biol Med (2016) 0.76

Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review. PLoS One (2017) 0.75

Emerging concepts in liquid biopsies. BMC Med (2017) 0.75

Detection of copy number alterations in cell-free tumor DNA from plasma. BBA Clin (2017) 0.75

Single-cell transcriptomics: an emerging tool in the study of cardiometabolic disease. J Transl Med (2014) 0.75

Non-blood circulating tumor DNA detection in cancer. Oncotarget (2017) 0.75

Articles cited by this

Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35

Cancer genome landscapes. Science (2013) 25.33

Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33

Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37

Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54

Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87

Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77

Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 7.99

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77

Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med (2000) 6.98

A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86

Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59

Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54

Dissecting the metastatic cascade. Nat Rev Cancer (2004) 6.32

Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18

Exploring the genomes of cancer cells: progress and promise. Science (2011) 6.16

Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08

Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69

Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell (2012) 5.62

Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science (2012) 5.50

Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16

Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68

Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59

Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett (2007) 4.35

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11

Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol (2012) 3.98

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92

Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90

Circulating tumor cells: liquid biopsy of cancer. Clin Chem (2012) 3.87

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2009) 3.79

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74

Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61

Genome-wide single-cell analysis of recombination activity and de novo mutation rates in human sperm. Cell (2012) 3.52

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol (2008) 3.44

RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature (2012) 3.40

Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem (2012) 3.35

Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med (1996) 2.95

Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med (1996) 2.85

Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector. Sci Transl Med (2012) 2.82

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76

Circulating epithelial cells in patients with benign colon diseases. Clin Chem (2011) 2.57

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med (2013) 2.28

The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med (2013) 2.18

Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17

Probing meiotic recombination and aneuploidy of single sperm cells by whole-genome sequencing. Science (2012) 2.14

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11

Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology (1989) 2.03

Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev (2010) 2.03

The genetic basis for cancer treatment decisions. Cell (2012) 2.03

Clinical implications of cancer self-seeding. Nat Rev Clin Oncol (2011) 1.77

Rare Cell Capture in Microfluidic Devices. Chem Eng Sci (2011) 1.68

Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem (2011) 1.60

Biologic challenges in the detection of circulating tumor cells. Cancer Res (2012) 1.55

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer (2013) 1.51

Cancer pharmacogenomics: early promise, but concerted effort needed. Science (2013) 1.48

Modeling metastasis in the mouse. Curr Opin Pharmacol (2010) 1.46

Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res (2004) 1.40

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer (2013) 1.27

High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer (2003) 1.25

Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett (2013) 1.24

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer (2010) 1.23

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer (2010) 1.20

Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A (2002) 1.15

Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer (2012) 1.13

Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res (2012) 1.12

Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 1.01

EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res (2012) 0.97

A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs (2010) 0.96

Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem (2010) 0.94

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol (2010) 0.88

Single circulating tumor cell sequencing for monitoring. Oncotarget (2013) 0.84